TG Therapeutics
TGTX
About: TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Employees: 352
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
37% more call options, than puts
Call options by funds: $106M | Put options by funds: $77M
36% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 104
1.38% more ownership
Funds ownership: 62.65% [Q1] → 64.03% (+1.38%) [Q2]
5% less funds holding
Funds holding: 371 [Q1] → 351 (-20) [Q2]
6% less capital invested
Capital invested by funds: $3.88B [Q1] → $3.65B (-$232M) [Q2]
25% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 63
29% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 5 (-2) [Q2]
Financial journalist opinion
Based on 7 articles about TGTX published over the past 30 days
